Home » TargeGen Initiates Multi-Center Phase II Clinical Trial Of TG100801
TargeGen Initiates Multi-Center Phase II Clinical Trial Of TG100801
TargeGen announced that it has initiated a multicenter Phase II clinical trial of topically applied TG100801 in patients with age-related macular degeneration (AMD).
Currently approved treatments for AMD require repeated injection into the eye and act primarily by reducing vascular endothelial growth factor (VEGF)-mediated retinal leakage, TargeGen said.
TG100801 is administered non-invasively as an eye drop and is designed to suppress VEGF-mediated leakage and additional kinase targets associated with inflammation, edema and angiogenesis that are the pathological hallmarks of AMD and other back-of-the-eye diseases, including diabetic macular edema and proliferative diabetic retinopathy, the company added.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May